Bank of America raised its price target following positive news regarding Alvotech, a licensing agreement for biosimilar commercialization, and the FDA closing an inspection after quality issues.
2 reports, 1 independent
Updated Aug 24
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bank of America raised its price target following positive news regarding Alvotech, a licensing agreement for biosimilar commercialization, and the FDA closing an inspection after quality issues.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Alvotech
biotechnology company
Nothing else this week.
-
Bank of America
American multinational banking and financial services corporation
Related events
- Bank of America analysts covered Micron Technology, raising price targets after the company beat EPS estimates and forecasting HBM market growth.
- Stephens and Bank of America raised price targets for Darden Restaurants.
- Bank of America reiterated its Buy rating and maintained the price target for Costco on May 27, 2026.
- Bank of America reiterated a 'buy' rating on stock while companies like Starbucks and Dutch Bros Inc operate and compete in the Texas QSR market.
- Eli Lilly and Company filed institutional holdings reports with the SEC, while Bank of America raised price targets on the stock.